Results from a long-term open-label extension study of adjunctive buprenorphine/samidorphan combination in patients with major depressive disorder

Neuropsychopharmacology · Elsevier

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles